Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biotech Pharmaceutical Co., Ltd.
With
Sun Yat-sen University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed, histologically proven single supratentorial GBM (WHO grade 4);
EGFR positive;
\>50％ of the gross tumor volume removed by surgery；
Karnofsky performance score (KPS) ≥ 60;
Adequate renal function (creatinine ≤1.5×upper limit of normal \[ULN\] or creatinine clearance ≥ 60 mL/min), hepatic function (total bilirubin ≤1.5×ULN and serum transaminases ≤3×ULN), and hematologic function (white blood cell count ≥ 3,000/uL or absolute neutrophil count ≥ 1,500/uL, platelets ≥ 100,000/uL, and hemoglobin ≥ 10 g/dL).
Tumor tissue was required for central pathology review and re-checking EGFR and MGMT expression status;
An interval of 2 to 6 weeks between surgery and RT was required.
You may not be if
Negative EGFR expression;
Prior chemotherapy, anti-EGFR therapy, RT, or a history of malignancy in the previous 5 years;
Patients with severe complications or active infection;
Continuous vomiting that could interfere with the oral administration of TMZ;
